Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 2/2013

01-06-2013 | Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S.D. Katz, Section Editor)

Platelet Activating Factor in Heart Failure: Potential Role in Disease Progression and Novel Target for Therapy

Published in: Current Heart Failure Reports | Issue 2/2013

Login to get access

Abstract

Heart failure (HF) is a complex syndrome with cardiac, renal, neurohormonal and sympathetic nervous system’s manifestations, the pathogenesis of which among others is connected to inflammation. PAF has local and systemic effects pertaining to HF progression since it causes a negative inotropic effect, it induces arrhythmias, it induces apoptosis and it is involved in inflammation and atherosclerosis. In the present review the role of PAF in HF will be thoroughly presented along with the relevant data on PAF enzymes and the potential role of PAF metabolic circuit as a novel pharmacological target.
Literature
1.
•• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847. This publication is of major clinical importance since it presents the guidelines for diagnosis and treatment of heart failure.PubMedCrossRef
2.
Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.PubMedCrossRef
3.
Dixon DL, Griggs KM, Bersten AD, De Pasquale CG. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine. 2011;56:593–9.PubMedCrossRef
4.
Liu L, Zhao SP. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol. 1999;69:77–82.PubMedCrossRef
5.
Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979;254:9355–8.PubMed
6.
Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80:1669–99.PubMed
7.
Demopoulos C, Karantonis H, Antonopoulou S. Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105:705–16.CrossRef
8.
Zhao D, Chu WF, Wu L, et al. PAF exerts a direct apoptotic effect on the rat H9c2 cardiomyocytes in Ca2+-dependent manner. Int J Cardiol. 2010;143:86–93.PubMedCrossRef
9.
Detopoulou P, Nomikos T, Fragopoulou E, et al. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem. 2009;42:44–9.PubMedCrossRef
10.
• Detopoulou P, Fragopoulou E, Nomikos T, et al. Baseline and 6-week Follow-Up Levels of PAF and Activity of its Metabolic Enzymes in Patients With Heart Failure and Healthy Volunteers--A Pilot Study. Angiology 2012. doi:10.​1177/​0003319712458536​. This publication presents the whole metabolic circuit of PAF in heart failure patients along with the progression of the disease.
11.
Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta. 1995;1254:231–49.PubMedCrossRef
12.
Shindou H, Hishikawa D, Nakanishi H, et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells: cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase. J Biol Chem. 2007;282:6532–9.PubMedCrossRef
13.
Harayama T, Shindou H, Ogasawara R, Suwabe A, Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J Biol Chem. 2008;283:11097–106.PubMedCrossRef
14.
Snyder F. CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997;4:111–6.
15.
Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther. 2009;23:73–83.PubMedCrossRef
16.
Burghardt C, Janero D. The anoxic rat-heart myocyte produces and releases platelet activating (PAF) as a component of its ischemia-like pathology. J Mol Cell Cardiol. 1987;19:pS69.
17.
Levi R, Burke JA, Guo ZG, et al. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res. 1984;54:117–24.PubMedCrossRef
18.
Annable C, McManus L, Carey K, Pinckard R. Isolation of platelet-activating factor (PAF) from ischemic baboon myocardium. Fed Proc. 1985;44:1271.
19.
Montrucchio G, Alloatti G, Tetta C, et al. Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol. 1989;256:H1236–46.PubMed
20.
Janero DR, Burghardt C. Production and release of platelet-activating factor by the injured heart-muscle cell (cardiomyocyte). Res Commun Chem Pathol Pharmacol. 1990;67:201–18.PubMed
21.
Stahl GL, Lefer DJ, Lefer AM. PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart. Naunyn Schmiedeberg’s Arch Pharmacol. 1987;336:459–63.CrossRef
22.
Kenzora JL, Perez JE, Bergmann SR, Lange LG. Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. J Clin Invest. 1984;74:1193–203.PubMedCrossRef
23.
Loucks EB, Godin DV, Walley KR, et al. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart. Can J Cardiol. 2003;19:267–74.PubMed
24.
Kecskemeti V, Balogh I. Cardiac ultrastructural effects of the platelet-activating factor and its antagonist BN 52021. Exp Toxicol Pathol. 1995;47:463–70.PubMedCrossRef
25.
Evangelou A, Kalfakakou V, Benveniste J, Arnoux B. Inhibition of PAF-acether effects on isolated guinea pig hearts by zinc ions (Zn2+). Biol Trace Elem Res. 1995;50:43–55.PubMedCrossRef
26.
Camussi G, Alloatti G, Montrucchio G, Meda M, Emanuelli G. Effect of platelet activating factor on guinea-pig papillary muscle. Experientia. 1984;40:697–9.PubMedCrossRef
27.
Wahler GM, Coyle DE, Sperelakis N. Effects of platelet-activating factor on single potassium channel currents in guinea pig ventricular myocytes. Mol Cell Biochem. 1990;93:69–76.PubMedCrossRef
28.
Massey CV, Kohout TA, Gaa ST, Lederer WJ, Rogers TB. Molecular and cellular actions of platelet-activating factor in rat heart cells. J Clin Invest. 1991;88:2106–16.PubMedCrossRef
29.
Alloatti G, Levi R, Malan D, et al. Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc Res. 2003;60:242–9.PubMedCrossRef
30.
Church DJ, van der Bent V, Vallotton MB, Capponi AM, Lang U. Calcium influx in platelet activating factor-induced atrial natriuretic peptide release in rat cardiomyocytes. Am J Physiol. 1994;266:E403–9.PubMed
31.
Gupta JB, Prasad M, Kalra J, Prasad K. Platelet-activating-factor-induced changes in cardiovascular function and oxyradical status of myocardium in presence of the PAF antagonist CV-6209. Angiology. 1994;45:25–36.PubMedCrossRef
32.
Montrucchio G, Alloatti G, Mariano F, et al. Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart. Am J Pathol. 1993;142:471–80.PubMed
33.
Tselepis AD, Evangelou A, Tsoukatos D, Demopoulos CA, Kapoulas VM. Electrocardiographic alterations induced by AGEPC in Wistar rats in relation to its hypotensive and hematologic effects. Comp Biochem Physiol C. 1987;87:41–6.PubMedCrossRef
34.
Robertson DA, Wang DY, Lee CO, Levi R. Negative inotropic effect of platelet-activating factor: association with a decrease in intracellular sodium activity. J Pharmacol Exp Ther. 1988;245:124–8.PubMed
35.
Montrucchio G, Alloatti G, Mariano F, Tetta C, Emanuelli G, et al. Cardiovascular alterations in the rabbit infused with platelet activating factor (PAF): effect of kadsurenone, a PAF-receptor antagonist. Int J Tissue React. 1986;8:497–504.PubMed
36.
Hoffman BF, Guo SD, Feinmark SJ. Arrhythmias caused by platelet activating factor. J Cardiovasc Electrophysiol. 1996;7:120–33.PubMedCrossRef
37.
Barbuti A, Ishii S, Shimizu T, Robinson RB, Feinmark SJ. Block of the background K(+) channel TASK-1 contributes to arrhythmogenic effects of platelet-activating factor. Am J Physiol Heart Circ Physiol. 2002;282:H2024–30.PubMed
38.
Nakaya H, Tohse N. Electrophysiological effects of acetyl glyceryl ether phosphorylcholine on cardiac tissues: comparison with lysophosphatidylcholine and long chain acyl carnitine. Br J Pharmacol. 1986;89:749–57.PubMedCrossRef
39.
Mest HJ, Riedel A, Braquet P, Meyer E. The arrhythmogenic effect of platelet activating factor (PAF) is inhibited by PAF antagonist and by substances influencing eicosanoids. Biomed Biochim Acta. 1988;47:S219–23.PubMed
40.
Cakici I, Mataraci N, Ersoy S, et al. Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias. Pharmacol Toxicol. 1995;76:343–7.PubMedCrossRef
41.
Guillon JM, Rochette L, Baranes J. Effects of Ginkgo biloba extract on 2 models of experimental myocardial ischemia. Presse Med. 1986;15:1516–9.PubMed
42.
Riedel A, Mest HJ. The effect of PAF (platelet-activating factor) on experimental cardiac arrhythmias and its inhibition by substances influencing arachidonic acid metabolites. Prostaglandins Leukot Med. 1987;28:103–9.PubMedCrossRef
43.
Muirhead EE, Byers LW, Desiderio DM, Brooks B, Brosius WM. Antihypertensive lipids from the kidney: alkyl ether analogs of phosphatidylcholine. Fed Proc. 1981;40:2285–90.PubMed
44.
•• Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med (Maywood). 2011;236:390–401. The present review provides a thorough presentation of the role of PAF in ischemia/ reperfusion with a plethora of experimental examples.CrossRef
45.
Blank ML, Hall MN, Cress EA, Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. Biochem Biophys Res Commun. 1983;113:666–71.PubMedCrossRef
46.
McGowan HM, Vandongen R, Kelly LD, Hill KJ. Increased levels of platelet-activating factor (1-O-alkyl-2-acetylglycerophosphocholine) in blood after reversal of renal clip hypertension in the rat. Clin Sci (Lond). 1988;74:393–6.
47.
Eldar M, Lysko PG, Schulhoff N, et al. Effects of coronary angioplasty on plasma platelet-activating factor in man. J Lipid Mediat. 1992;5:313–9.PubMed
48.
Piper PJ, Stewart AG. Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Br J Pharmacol. 1986;88:595–605.PubMedCrossRef
49.
Piper PJ, Stewart AG. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists. Br J Pharmacol. 1987;90:771–83.PubMedCrossRef
50.
Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. Semin Thromb Hemost. 2012;38:506–14.PubMedCrossRef
51.
Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci. 2003;40:643–72.PubMedCrossRef
52.
Stewart AG, Dubbin PN, Harris T, Dusting GJ. Platelet-activating factor may act as a second messenger in the release of eicosanoids and superoxide anions from leukocytes and endothelial cells. Proc Natl Acad Sci U S A. 1990;87:3215–9.PubMedCrossRef
53.
Rouis M, Nigon F, Chapman MJ. Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages. Biochem Biophys Res Commun. 1988;156:1293–301.PubMedCrossRef
54.
Gaut JP, Heinecke JW. Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med. 2001;11:103–12.PubMedCrossRef
55.
Liapikos TA, Antonopoulou S, Karabina SP, et al. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta. 1994;1212:353–60.PubMedCrossRef
56.
Rios FJ, Gidlund M, Jancar S. Pivotal role for platelet-activating factor receptor in CD36 expression and oxLDL uptake by human monocytes/macrophages. Cell Physiol Biochem. 2011;27:363–72.PubMedCrossRef
57.
Beaudeux JL, Said T, Ninio E, et al. Activation of PAF receptor by oxidised LDL in human monocytes stimulates chemokine releases but not urokinase-type plasminogen activator expression. Clin Chim Acta. 2004;344:163–71.PubMedCrossRef
58.
Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Inflammation as an early component of atherosclerosis and vascular damage–a role for P-selectin and platelet-activating factor. Jpn Circ J. 1996;60:137–41.PubMedCrossRef
59.
Handley DA, Arbeeny CM, Lee ML, Van Valen RG, Saunders RN. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology. 1984;8:137–42.PubMedCrossRef
60.
Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest. 1995;95:2297–303.PubMedCrossRef
61.
Takahashi T, Nishizawa Y, Hato F, et al. Neutrophil-activating activity and platelet-activating factor synthesis in cytokine-stimulated endothelial cells: reduced activity in growth-arrested cells. Microvasc Res. 2006;73:29–34.PubMedCrossRef
62.
McManus LM, Hanahan DJ, Pinckard RN. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest. 1981;67:903–6.PubMedCrossRef
63.
Klinger MH. Platelets and inflammation. Anat Embryol (Berl). 1997;196:1–11.CrossRef
64.
Rouis M, Nigon F, Lafuma C, Hornebeck W, Chapman MJ. Expression of elastase activity by human monocyte-macrophages is modulated by cellular cholesterol content, inflammatory mediators, and phorbol myristate acetate. Arteriosclerosis. 1990;10:246–55.PubMedCrossRef
65.
Antonopoulou S, Nomikos T, Karantonis HC, Fragopoulou E, Demopoulos CA. PAF, a potent lipid mediator In: Bioactive Phospholipids. Role in Inflammation and Atheroslerosis. Edited by Tselepis AD. India: Research Signpost; 2009:85–134.
66.
Feliste R, Perret B, Braquet P, Chap H. Protective effect of BN 52021, a specific antagonist of platelet-activating factor (PAF-acether) against diet-induced cholesteryl ester deposition in rabbit aorta. Atherosclerosis. 1989;78:151–8.PubMedCrossRef
67.
Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol. 2006;48:56–66.CrossRef
68.
Sadat U. Signaling pathways of cardioprotective ischemic preconditioning. Int J Surg. 2009;7:490–8.PubMedCrossRef
69.
Leary PJ, Rajasekaran S, Morrison RR, et al. A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation. Am J Physiol Heart Circ Physiol. 2008;294:H2775–84.PubMedCrossRef
70.
Valone FH, Epstein LB. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. J Immunol. 1988;141:3945–50.PubMed
71.
Zhang GQ, Tao YK, Li XL, et al. Investigation of platelet activating factor (PAF) in acute myocardial infarction. Chin J Emerg Med. 2010;19:1304–7.
72.
Szmit S, Jank M, Maciejewski H, et al. Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure. J Appl Genet. 2010;51:353–68.PubMedCrossRef
73.
Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;103:2495–500.PubMedCrossRef
74.
•• The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–44. The present paper presents the combined results of several large studies concerning the role of Lp-PLA2 in cardiovascular disease.CrossRef
75.
Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411–6.PubMedCrossRef
76.
Mohler 3rd ER, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51:1632–41.PubMedCrossRef
77.
Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172–82.PubMedCrossRef
78.
Wang WY, Zhang J, Wu WY, et al. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS One. 2011;6:e23425.PubMedCrossRef
79.
Hu MM, Zhang J, Wang WY, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin. 2011;32:1253–8.PubMed
80.
White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010;160:655–61.PubMedCrossRef
81.
van Vark LC, Kardys I, Bleumink GS, et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. Eur Heart J. 2006;27:2346–52.PubMedCrossRef
82.
Suzuki T, Solomon C, Jenny NS, et al. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail. 2009;2:429–36.PubMedCrossRef
83.
Gerber Y, Dunlay SM, Jaffe AS, et al. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis. 2009;203:593–8.PubMedCrossRef
84.
Moldoveanu E, Serban M, Marta DS, Serban I, Huica R. Lipoprotein-associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction. Biomarkers. 2011;16:587–9.PubMedCrossRef
85.
Charniot JC, Khani-Bittar R, Albertini JP, et al. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. Int J Cardiol 2012. doi:10.​1016/​j.​ijcard.​2012.​09.​054.
86.
Gullestad L, Ueland T, Vinge LE, et al. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012;122:23–35.
87.
Alloatti G, Montrucchio G, Mariano F, et al. Protective effect of verapamil on the cardiac and circulatory alterations induced by platelet-activating factor. J Cardiovasc Pharmacol. 1987;9:181–6.PubMedCrossRef
88.
Kelefiotis D, Lanara E, Vakirtzi-Lemonias C, et al. Study of digoxin as inhibitor of the in vivo effects of acetyl glyceryl ether phosphorylcholine (AGEPC) in mice. Life Sci. 1988;42:623–33.PubMedCrossRef
89.
Chrysohoou C, Pitsavos C, Metallinos G, et al. Cross-sectional relationship of a Mediterranean type diet to diastolic heart function in chronic heart failure patients. Hear Vessel. 2012;27:576–84.CrossRef
90.
Nomikos T, Fragopoulou E, Antonopoulou S. Food ingredients and lipid mediators. Curr Nutr Food Sci. 2007;3:255–76.CrossRef
91.
Fragopoulou E, Demopoulos CA, Antonopoulou S. Lipid minor constituents in wines. A biochemical approach in the French paradox. Int J Wine Res. 2009;1:131–43.
92.
Karantonis HC, Antonopoulou S, Perrea DN, et al. In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. Nutr Metab Cardiovasc Dis. 2006;16:174–85.PubMedCrossRef
93.
Antonopoulou S, Fragopoulou E, Karantonis HC, et al. Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. J Med Food. 2006;9:356–62.PubMedCrossRef
94.
95.
Godfrey V, Farquharson C, Macdonald JE, Yee CM, Struthers AD. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol. 2007;117:282–4.PubMedCrossRef
96.
Tsantila N, Tsoupras AB, Fragopoulou E, et al. In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011;62:209–18.PubMedCrossRef
97.
Heller R, Bussolino F, Ghigo D, et al. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem Pharmacol. 1992;44:223–9.PubMedCrossRef
98.
Tolins JP, Melemed A, Sulciner D, Gustafson KS, Vercellotti GM. Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cells. Lipids. 1991;26:1218–22.PubMedCrossRef
99.
Schror K, Felsch A. Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation. Agents Actions Suppl. 1992;38(Pt 3):209–16.PubMed
100.
White HL, Faison LD. Inhibition of lyso-PAF: acetyl-CoA acetyltransferase by salicylates and other compounds. Prostaglandins. 1988;35:939–44.PubMed
Metadata
Title
Platelet Activating Factor in Heart Failure: Potential Role in Disease Progression and Novel Target for Therapy
Publication date
01-06-2013
Published in
Current Heart Failure Reports / Issue 2/2013
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-013-0131-2

Other articles of this Issue 2/2013

Current Heart Failure Reports 2/2013 Go to the issue

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section Editor)

Chemohypersensitivity and Autonomic Modulation of Venous Capacitance in the Pathophysiology of Acute Decompensated Heart Failure

Management of Heart Failure (TE Meyer, Section Editor)

Current Status of Cell-Based Therapy for Heart Failure

Management of Heart Failure (T.E. Meyer, Section Editor)

Defining the Role for Percutaneous Mechanical Circulatory Support Devices for Medically Refractory Heart Failure

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section Editor)

Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications

Management of Heart Failure (TE Meyer, Section Editor)

Treating Hypertension in Patients with Left Ventricular Dysfunction: Hitting the Fairway and Avoiding the Rough

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S.D. Katz, Section Editor)

High-Intensity Aerobic Interval Exercise in Chronic Heart Failure

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits